Publications
83
Citations
2,529
Est. group size
—
Recurring co-author estimate
Active years
50
Publishing since 1977
Cynthia D. Brown studies cystic fibrosis, a genetic condition that mainly affects the lungs and digestive system, with a focus on the era of newer drugs called CFTR modulators that correct the underlying protein defect. Her work spans how these therapies affect patients' physical and mental well-being, treatment adherence, and social factors, as well as related topics like CFTR gene variants and cancer risk and other lung diseases. She also examines real-world outcomes using patient surveys, health records, and clinical trials.
Publication activity has grown steadily over the last decade, roughly doubling from earlier years to a recent peak of about eight papers per year.
Generated by claude-opus-4-8 from public bibliographic data · Jul 9, 2026
Typically publishes in teams of ~6 · 7% small-team papers (≤3 authors) · across 19 venues
- Pulmonary Outcomes in People with Cystic Fibrosis who Stop Chronic Daily Therapies: The HERO-2 Study
Annals of the American Thoracic Society · 2026
- Case Series of Sustained Fluid‐Associated Weight Gain Following Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator Therapy
Pediatric Pulmonology · 2026
- Pathogenic CFTR variants as cancer risk modifiers: Findings from the all of us cohort
Journal of Cystic Fibrosis · 2025
- Nebulized tranexamic acid for hemoptysis in critically and non-critically ill patients: A retrospective analysis
The Journal of Critical Care Medicine · 2025
- The Impact of Personal-Level Social Networks on Treatment Adherence, Depression, Anxiety, and Perceived Stigma Among Adults with Cystic Fibrosis: An Egocentric Network Analysis
International Journal of Behavioral Medicine · 2025
- Gender Differences in Mental Well‐Being Among Children and Adults With Cystic Fibrosis in the Modulator Era
Pediatric Pulmonology · 2025
- Physical well-being and burden of care in adults on modulator therapy: A mixed methods study of patient-reported experiences from the Well-ME survey
Journal of Cystic Fibrosis · 2025
- Baseline Characteristics and Self‐Reported Use of Chronic Daily Therapies of the Home Reported Outcomes With CFTR Modulator Therapy (HERO‐2) Cohort
Pediatric Pulmonology · 2025
- 722 Changes in Medicaid claims for chronic medications for cystic fibrosis
Journal of Cystic Fibrosis · 2025
- Enrichment of Germline Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Pathogenic Variants in Patients With Solid Tumors: Evidence for Increased Cancer Risk
Pediatric Pulmonology · 2025
- Using Real-World Research to Study the Impact of Chronic Daily Therapy Discontinuation in Cystic Fibrosis
CHEST Pulmonary · 2024
- 502 Prevalence of cannabidiol use in people with CF
Journal of Cystic Fibrosis · 2024
- 469 Impact of social complexity on long-term health outcomes and survival in young adults with cystic fibrosis
Journal of Cystic Fibrosis · 2024
- Predictors of Selective Serotonin Reuptake Inhibitor Treatment Failure in Persons With Cystic Fibrosis
Pediatric Pulmonology · 2024
- Prevalence of cannabidiol use in persons with cystic fibrosis
Pediatric Pulmonology · 2024
- Journal of Cystic Fibrosis×10
- Pediatric Pulmonology×10
- The Lancet Respiratory Medicine×2
- Annals of the American Thoracic Society×2
- Respiratory medicine×2
- David W. Reid
Medicine · University of Michigan
- Charles Clem
Medicine · Indiana University
- Don B. Sanders
Medicine · Indiana University
- Kevin J. Psoter
Medicine · University of Michigan
- Katelyn Krivchenia
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Sep 1, 2026.
Claim or correct this profile